Latest Indivior News & Updates

See the latest news and media coverage for Indivior. We track all announcements, press releases, and industry mentions in real time, all in one place.

Indivior

Specialty pharmaceutical company focused on opioid use disorder

indivior.com

Headquarters: Richmond, United States
Company type: Public company
Number of employees: 1,000–5,000
Industry: Pharmaceuticals

Last updated Today

Latest news about Indivior

In short: Indivior agreed to a $2.2 billion merger with Supernus and reported Q2 2026 earnings that surpassed analyst expectations.

Company announcements

Yesterday Indivior

Indivior declares special cash dividend contingent on merger

The $8.13 per share dividend pays after Nov 2 merger with Supernus closes. Indivior won't pay if the deal fails.

August 6 Indivior

Indivior completed its delisting from the London Stock Exchange

The secondary listing ended July 25, 2025; Nasdaq remains its primary listing.

August 3 Indivior

Indivior and Supernus to combine in $2.2B merger

The tax-free all-stock merger of equals expects $125M annual cost synergies and will create Supernus, Inc. with Jack Khattar as CEO.

August 3 Indivior

Indivior reports Q2 2026 financial results and raises guidance

Total net revenue rose 14% to $343 million, with record SUBLOCADE revenue and adjusted EBITDA, and the company announced a merger with Supernus.

Media coverage

Yesterday Yahoo Finance

INDV Stock Alert: Halper Sadeh LLC is Investigating Whether Indivior Pharmaceuticals, Inc. is Obtaining a Fair Price for its Shareholders

NEW YORK--(BUSINESS WIRE)--Aug 29, 2026...

Never miss news about Indivior

Track Indivior and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Indivior competitors & trending companies

Browse news for competitors to Indivior and other trending companies.